I like this chart a lot actually. if we bounce off this crossroad, we will reach the moon eventually. Adding a little to my long position.
Have a terrific weekend!
Reuters
Adage Capital Partners GP LLC Dissolves Share Stake In Moderna, Takes In Gilead Sciences!
Reuters:
Germany requests 5% of EU supply of remdesivir
Germany has requested around 5% of the supply of remdesivir under a six-month European Union supply deal, its health ministry said on Monday, despite criticism of the deal due to a lack of evidence about the...
NASDAQ:GILD
Based on technical analysis, the idea is to go long only if the bottom support level of 60 USD will not be broken.
Target prices are:
1. 68USD
2. 80 USD
I also wrote on the huge upside potential of Gilead when they acquired Immunomedics for $21 billion.
The acquisition expands Gilead's portfolio of treatments for various types of cancer.
On 9/10/2020 Oppenheimer Brokerage Boosted Price Target to Outperform from...
Based on Technical Analysis the best option is to hold and wait the end of the price retracement before going long.
Trump has been treated with Gilead Sciences remdesivir.
The acquisition will expand Gilead's portfolio of treatments for various types of cancer.
The deal with Immunomedics provides Gilead (GILD) with Trodelvy, an antibody drug for advanced triple-negative breast cancer. The drug was given accelerated FDA approval in April. (Source CNN Business).
Sell on 1 hour chart
Buy on 7h chart
Sell on 3 day chart, but a trend...
📍 The effect of Remdesivir...
The power to unlock the all time highs via Covid is systematically, within reach rather fast, due to the nature of drug prices which are inelastic. The effect of Gilead being treated as utility is heightened by DT putting the big orders in.
Compare the following two diagrams:
...
June 29 (Reuters) - Gilead Sciences Inc GILD on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.
Remdesivir is expected to be in high demand as one of the only treatments shown to alter the course of COVID-19. After...
Technical Analysis:
HOLD BEFORE GOING LONG -Wait that the resistance level will be broken before buying.
Fundamental Information:
Gilead Was Approached by AstraZeneca About Potential Merger
It is trading below RSI 50 and 50SMA which put the stock in bearish. After fast dropped down, it may pull back to $75. However, if there will be no any good news will support the stock most likely it will continue descending.
If you like my charts useful, please leave me "like"
thx
Gilead
WHO mistakenly posted study results that appeared to show that a leading potential coronavirus treatment failed to help patients
www.businessinsider.my
U.S. FDA approved Gilead Sciences Inc.’s experimental antiviral drug, remdesivir, for use as it’s showing good signs of helping hospitalised patients recover more quickly from Corona Virus.
From a Trend Analysis perspective - price action has been very choppy with lots of buying and selling in an almost Up-trending consolidation.
We expect Gilead to push...
